External broker reports(aggregated public sources), CCZ Statton Equities

CCZ Statton Equities

CCZ is a leading Australian stockbroking firm providing stockbroking and wealth generation services to private clients and institutional investors. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>Eisai Co.,Ltd has announced its Lecanemab confirmatory phase 3 study meeting its primary and secondary endpoints.</li><li>The drug reduced clinical cognitive decline by 27% compared to a placebo in a study involving 1,795 participants with early Alzheimer's disease.</li><li>Eisai will continue to seek drug approval for Lecanemab in the US, Japan and Europe.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Eisai Co.,Ltd has announced its Lecanemab confirmatory phase 3 study meeting its primary and secondary endpoints.The drug reduced clinical cognitive decline by 27% compared to a placebo in a study involving 1,795 participants with early Alzheimer's disease.Eisai will continue to seek drug approval for Lecanemab in the US, Japan and Europe.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Cogstate - Lecanemab Strikes 'home Run' for Alzheimer's Drug Development

Cogstate Ltd

Cogstate - Lecanemab Strikes 'home Run' for Alzheimer's Drug Development